AGLink® ADC Conjugation Kit (DBCO, DAR2&4,1mg)

• Background:

  Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGLink® ADC conjugation kit is designed to conjugate mAb with DBCO though site-specific enzymatic reaction.

• Description:

  AGLink® ADC Conjugation Kit (DBCO, DAR2&4,1mg)

• Target:

  DBCO

• Applications:

  AGLink® ADC Conjugation Kit (DBCO, DAR2&4,1mg) is designed to conjugate 1mg mAb with DBCO through site-specific enzymatic reaction.

• Stability:

  BoxA: The unopened kit is stable for 18 months from the date of manufacture if stored under temperature ≤ -20°C. The opened kit should be stored according to components table. BoxB: The unopened kit is stable for 18 months from the date of manufacture if stored under 4°C. The opened kit should be stored according to components table.

• Format:

  Solid

• Shipping Conditions:

  Blue ice

• Storage Conditions:

  -20°C

• Package Size:

  1Reaction*1